Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers

Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A. Cassier, Carlos Gomez-Roca, Iphigenie Korakis, Peter Grell, Aung Naing, Patricia LoRusso, Romana Mikyskova, Nada Podzimkova, Milan Reinis, Kaissa Ouali, Andreu Schoenenberger, Joachim Kiemle-Kallee, Sascha Tillmanns, Richard Sachse, Ulrich Moebius, Radek Spisek, David Bechard, Lenka Palova Jelinkova, Irena Adkins, Aurelien Marabelle

Open source

DOI: 10.1016/j.xcrm.2025.101967
Published: 2025-02
Container: Cell Reports Medicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.xcrm.2025.101967,
  title = {Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers},
  author = {Stephane Champiat and Elena Garralda and Vladimir Galvao and Philippe A. Cassier and Carlos Gomez-Roca and Iphigenie Korakis and Peter Grell and Aung Naing and Patricia LoRusso and Romana Mikyskova and Nada Podzimkova and Milan Reinis and Kaissa Ouali and Andreu Schoenenberger and Joachim Kiemle-Kallee and Sascha Tillmanns and Richard Sachse and Ulrich Moebius and Radek Spisek and David Bechard and Lenka Palova Jelinkova and Irena Adkins and Aurelien Marabelle},
  year = {2025},
  journal = {Cell Reports Medicine},
  doi = {10.1016/j.xcrm.2025.101967},
  url = {https://doi.org/10.1016/j.xcrm.2025.101967}
}

RIS

TY  - JOUR
TI  - Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers
AU  - Stephane Champiat
AU  - Elena Garralda
AU  - Vladimir Galvao
AU  - Philippe A. Cassier
AU  - Carlos Gomez-Roca
AU  - Iphigenie Korakis
AU  - Peter Grell
AU  - Aung Naing
AU  - Patricia LoRusso
AU  - Romana Mikyskova
AU  - Nada Podzimkova
AU  - Milan Reinis
AU  - Kaissa Ouali
AU  - Andreu Schoenenberger
AU  - Joachim Kiemle-Kallee
AU  - Sascha Tillmanns
AU  - Richard Sachse
AU  - Ulrich Moebius
AU  - Radek Spisek
AU  - David Bechard
AU  - Lenka Palova Jelinkova
AU  - Irena Adkins
AU  - Aurelien Marabelle
PY  - 2025
JO  - Cell Reports Medicine
DO  - 10.1016/j.xcrm.2025.101967
UR  - https://doi.org/10.1016/j.xcrm.2025.101967
ER  -

APA

Champiat, S., Garralda, E., Galvao, V., Cassier, P. A., Gomez-Roca, C., Korakis, I., Grell, P., Naing, A., LoRusso, P., Mikyskova, R., Podzimkova, N., Reinis, M., Ouali, K., Schoenenberger, A., Kiemle-Kallee, J., Tillmanns, S., Sachse, R., Moebius, U., Spisek, R., Bechard, D., Jelinkova, L. P., Adkins, I., & Marabelle, A. (2025). Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2025.101967

Source records

crossref · retrieved 2026-09-27T02:06:57.710Z